Supernus Pharmaceuticals, Inc.SUPNNASDAQ
LOADING
|||
Switch Symbol:
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +14.17% | +5.99% | +4.30% | -1.71% | +9.34% |
| Gross Profit Growth | +17.74% | +2.33% | +5.28% | -1.19% | -9.07% |
| EBITDA Growth | +104.89% | +99.54% | +7.79% | -13.96% | -156.26% |
| Operating Income Growth | +401.90% | +0.00% | +0.00% | -46.20% | -247.46% |
| Net Income Growth | +0.00% | +1204.51% | -9637.90% | +12.97% | -217.20% |
| EPS Growth | +0.00% | +1202.33% | -10600.00% | +11.11% | -214.29% |
| EPS Diluted Growth | +0.00% | +1167.61% | -10600.00% | +11.11% | -215.94% |
| Weighted Average Shares Growth | +0.99% | +1.64% | +1.94% | +1.90% | +2.26% |
| Weighted Average Shares Diluted Growth | +2.58% | +2.56% | +0.43% | +1.65% | +0.96% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +49.18% | -1.23% | -20.32% | +64.31% | -215.22% |
| Free Cash Flow Growth | +49.25% | -1.78% | -20.66% | +63.33% | -215.89% |
| Receivables Growth | +2.57% | -1.44% | -1.42% | -7.65% | +17.77% |
| Inventory Growth | -23.36% | -29.86% | -34.17% | -35.41% | +24.10% |
| Asset Growth | +4.48% | +7.08% | +3.31% | +5.06% | +5.74% |
| Book Value per Share Growth | +9.33% | +10.59% | +8.82% | +9.04% | +1.92% |
| Debt Growth | -9.85% | -17.47% | -23.32% | -20.52% | -17.64% |
| R&D Expense Growth | +28.17% | +22.70% | +8.01% | -15.54% | +1.14% |
| SG&A Expenses Growth | -15.66% | -2.30% | +3.96% | +8.90% | +157.59% |